Since NGAL levels can be influenced by extrarenal factors such as systemic inflammation, chronic kidney disease, and other non-renal conditions, we applied several measures to improve its specificity as a biomarker for AKI. This evidence concerns the gene LCN2 and chronic kidney disease.